Omaron - instructions for use, reviews, analogs and forms of release (tablets 400 + 25 mg) of the drug for the treatment of circulatory insufficiency, migraine, motion sickness, the consequences of stroke in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Omaron. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Omaron in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Omaron in the presence of existing structural analogs.Use for the treatment of circulatory failure, motion sickness, depression, the consequences of stroke in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Omaron - Combined drug with antihypoxic, nootropic and vasodilating effect.

Piracetam (active ingredient of Omaron) activates metabolic processes in the brain by enhancing energy and protein metabolism, accelerating the utilization of glucose by cells and increasing their resistance to hypoxia, improves interneuronal transmission in the central nervous system, improves regional blood flow in the ischemic zone.

Cinnarizine is a selective blocker of slow calcium channels, inhibits the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, reduces the tone of the smooth muscles of arterioles, reduces their response to biogenic vasoconstrictors (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with respect to cerebral vessels, enhancing the antihypoxic effect of piracetam), without having a significant effect on blood pressure.It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood.

Composition

Piracetam + Cinnarizine + auxiliary substances.

Pharmacokinetics

After ingestion, Piracetam and cinnarizine are quickly and almost completely absorbed into the digestive tract. The bioavailability of piracetam is about 100%. Bioavailability of cinnarizine increases in an acidic environment. Pyracetam does not bind to blood plasma proteins. Penetrates through the blood-brain barrier (GEB) and placental barriers, to all organs and tissues, and through the filter membranes used in hemodialysis. In studies on animals, it was found that pyracetam selectively accumulates in the tissues of the cerebral cortex, mainly in the frontal, parietal and occipital lobes, the cerebellum and basal ganglia. The binding of cinnarizine to plasma proteins is 91%. 1-4 h after ingestion is found in the liver, kidneys, heart, lungs, spleen and brain. Piracetam is practically not metabolized in the body.Cinnarizine is actively and completely metabolized by dealkylation; the process of metabolism begins 30 minutes after ingestion. More than 95% of the ingested dose of pyracetam is excreted by the kidneys unchanged by renal filtration for 30 hours. In patients with hepatic insufficiency, the pharmacokinetics of piracetam does not change. Cinnarizine is excreted from the body in the form of metabolites (1/3 - by the kidneys, 2/3 - through the intestine).

Indications

As part of complex therapy:

• insufficiency of cerebral circulation (atherosclerosis of cerebral vessels, recovery period after ischemic and hemorrhagic stroke);
• encephalopathy post-toxication or post-traumatic;
• depression;
• psychoorganic syndrome with predominance of asthenia and adynamia;
• vestibular disorders;
• Meniere's syndrome;
• the backwardness of intellectual development in children;
• prevention of migraine;
• prevention of kinetosis (motion sickness) in adults and children.

Forms of release

Tablets 400 mg + 25 mg.

Instructions for use and dosage

Inside, during or after a meal.

Adults - 1-2 tablets 3 times a day for 1-3 months, depending on the severity of the disease.It is possible to conduct repeated courses of treatment - 2-3 times a year.

Children older than 5 years - 1-2 tablets 1-2 times a day. Do not use for more than 3 months.

For the prevention of kinetosis: adults - 1 tablet, children over 5 years - 1/2 tablet 30 minutes before the start of travel, with repeated admission (if necessary) every 6-8 hours.

In chronic renal failure (creatinine clearance 20-80 ml / min) - 1 tablet 2 times a day.

Side effect

• motor disinhibition;
• irritability;
• drowsiness;
• depression;
• asthenia;
• headache;
• dizziness;
• ataxia;
• exacerbation of epilepsy;
• extrapyramidal disorders;
• tremor;
• imbalance;
• decreased ability to concentrate;
• insomnia;
• excitation;
• anxiety;
• hallucinations;
• increased sexuality;
• decrease or increase in blood pressure;
• dyspeptic phenomena;
• a feeling of dryness in the mouth;
• nausea, vomiting;
• diarrhea;
• stomach ache;
• cholestatic jaundice;
• dermatitis;
• itching;
• skin rash;
• increase in body weight;
• angioedema;
• increased sweating;
• lupus-like syndrome;
• red flat herpes.

Contraindications

• severe hepatic impairment;
• severe renal failure (creatinine clearance less than 20 ml / min);
• hemorrhagic stroke; Parkinsonism (including Parkinson's disease);
• psychomotor agitation;
• Huntington's disease;
• pregnancy;
• lactation period;
• children under 5 years;
• lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome (the preparation contains lactose);
• hypersensitivity to the main and / or auxiliary components of the drug.

Application in pregnancy and lactation

The drug Omaron is contraindicated for use in pregnancy and lactation (breastfeeding).

Use in children

Children older than 5 years - 1-2 tablets 1-2 times a day. Do not use for more than 3 months.

For the prevention of kinetosis (motion sickness): children older than 5 years - 1/2 tablet 30 minutes before the start of travel, with repeated admission (if necessary) every 6-8 hours.

Contraindicated for children under 5 years.

special instructions

With prolonged use, it is recommended to monitor liver and kidney function (especially in patients with chronic renal failure).

During the treatment with Omarone in patients with arterial hypotension, a more significant decrease in blood pressure is possible.

It is not recommended to drink alcohol during treatment.

Distortion of the results of the doping test and allergic skin tests is possible; 4 days before the test, the drug should be withdrawn.

Impact on the ability to drive vehicles and manage mechanisms

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Drug Interactions

With simultaneous use, it is possible to strengthen the sedative effect of drugs that depress the CNS, as well as ethanol (alcohol), nootropic and antihypertensive agents.

Vasodilating agents increase the effect of Omaron.

Improves tolerability of antipsychotic drugs and tricyclic antidepressants.

With the simultaneous use of piracetam enhances the central effects of thyroid hormones (possible tremor, anxiety, irritability, sleep disturbances).

May intensify the effect of oral anticoagulants.

Analogues of the drug Omaron

Structural analogs for the active substance:

• Combbitropyl;
• NooCam;
• Piracesine;
• Fezam.

Analogues on the curative effect (means of motion sickness during motion):

• Avia Sea;
• Aviomarine;
• Aminalon;
• Anvifen;
• Validol;
• Vertigohel;
• Vinpotropil;
• Dramina;
• Kinedryl;
• Kokkulin;
• Combbitropyl;
• Noophen;
• Pipolphen;
• Pyrroxane;
• Ciel;
• Torekan;
• Fezam;
• Fenibut;
• Cinnarizine.

Similar medicines:

Other medicines: